@inproceedings{oai:repo.qst.go.jp:00054483,
 author = {Kokuryo, Daisuke and Aoki, Ichio and Saga, Tsuneo and 國領 大介 and 青木 伊知男 and 佐賀 恒夫},
 book = {Proc. Intl. Soc. Mag. Reson. Med.},
 month = {May},
 note = {In a previous study, we administered nanoparticles containing a MR contrast agent, a fluorescence dye and an anticancer drug to successfully detect and visualize subcutaneous and deep-seated tumor in the back muscle of a mouse cancer model [1, 2]. The tumor appeared as a signal enhancement in T1-weighted MRI. As the next step, it is desired to apply the nanoparticle to lung tumors and other pulmonary disease. Imaging of the lungs is difficult because of the low proton density, short T2* and respiratory motion. However, ultra-short echo-time (UTE) imaging [3, 4] has recently been utilized to evaluate signal changes in lung parenchyma for various animal disease models [5, 6]. Moreover, quantitative assessment of pulmonary perfusion with dynamic contrast-enhanced MRI has been performed for pulmonary embolism and tumor in humans [7, 8]. As a preliminary step toward visible disease therapeutics using nanoparticles, the present study evaluated changes to the signal intensity in lung parenchyma and me tastatic tumor using a positive contrast agent (Gd-DTPA) and UTE imaging.},
 pages = {972--972},
 title = {Evaluation of Gd-DTPA Contrast Enhancement of Lung and Metastatic Tumor with Ultra-Short Echo-Time Imaging},
 volume = {19},
 year = {2011}
}